Enliven Therapeutics, Inc. (ELVN)
(Real Time Quote from BATS)
$23.95 USD
-0.54 (-2.21%)
Updated May 14, 2024 03:36 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 5/16/24 |
---|---|
Current Quarter | -0.58 |
EPS Last Quarter | -0.47 |
Last EPS Surprise | 16.07% |
ABR | 1.00 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -2.16 |
Next Year | -2.81 |
EPS (TTM) | -2.19 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | NA |
# of Estimates | NA | NA | NA | NA |
High Estimate | NA | NA | NA | NA |
Low Estimate | NA | NA | NA | NA |
Year ago Sales | 0.00M | 0.00M | NA | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.58 | -0.61 | -2.16 | -2.81 |
# of Estimates | 1 | 1 | 2 | 2 |
Most Recent Consensus | NA | NA | -2.14 | -2.83 |
High Estimate | -0.58 | -0.61 | -2.14 | -2.79 |
Low Estimate | -0.58 | -0.61 | -2.17 | -2.83 |
Year ago EPS | -0.80 | -0.41 | -2.01 | -2.16 |
Year over Year Growth Est. | 27.50% | -48.78% | -7.46% | -30.32% |
Agreement - Estimate Revisions
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 0 | 0 | 1 | 0 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 0 | 0 | 0 | 1 |
Magnitude - Consensus Estimate Trend
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.58 | -0.61 | -2.16 | -2.81 |
7 Days Ago | -0.58 | -0.61 | -2.16 | -2.81 |
30 Days Ago | -0.58 | -0.61 | -2.16 | -2.81 |
60 Days Ago | NA | NA | -2.22 | -2.65 |
90 Days Ago | NA | NA | -2.37 | -2.72 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.58 | -0.61 | -2.16 | -2.81 |
Zacks Consensus Estimate | -0.58 | -0.61 | -2.16 | -2.81 |
Earnings ESP | 0.00% | 0.00% | 0.00% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Quarter Ending (3/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.47 | -0.51 | -0.41 | -0.80 | NA |
Estimate | -0.56 | -0.49 | -0.40 | -0.67 | NA |
Difference | 0.09 | -0.02 | -0.01 | -0.13 | -0.02 |
Surprise | 16.07% | -4.08% | -2.50% | -19.40% | -2.48% |
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more